Ion-827359

Author: jekf

August undefined, 2024

WebION-827359 : D.3.4: Pharmaceutical form : Inhalation solution: D.3.4.1: Specific paediatric formulation: No : D.3.7: Routes of administration for this IMP: Inhalation use: D.3.8 to … Web23 dec. 2024 · ION-827359 from Ionis is an inhalable Gapmer ASO formulation being developed for CF to assess the hyperactivity of ENaCs, though this trial has been paused due to safety concerns. The ASO sequence has the (S)-cEt modification that provides excellent target affinity and nuclease resistance.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …

WebION-827359 is a new inhaled investigational drug being developed for the purpose of treating lung disease symptoms in patients with COPD with Chronic Bronchitis. ION … Web12 aug. 2024 · The BALANCE-CFTM 1 phase II trial in patients with CF was safe, but did not demonstrate a potential for clinical benefit, and development has been terminated. … imprinted hard hats

A Study to Assess the Safety Tolerability and Efficacy of ION …

WebResults: ION-827359 was well-tolerated with an acceptable safety profile after multiple inhalations. The rate of adverse events was similar between ION-827359 and placebo … Web20 apr. 2024 · ION-827359 is a 2·5-generation antisense oligonucleotide drug targeted to reduce the ENaC protein. This study evaluated the safety, pharmacokinetics (PK), and … WebION-827359 is a chemically modified ASO, 16 nucleotides in length with a phosphorothioate backbone and constrained ethyl (cEt) modifications. In healthy volunteers the ASO was … imprinted in my brain

[PDF] Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in ...

Ion-827359

WebION-827359 SODIUM Code; ION-827359, SODIATED FORM Code; UNII Resources. Common Chemistry CAS Common Chemistry is an open community resource of the … WebNeurological Cancer Cardio-Renal Condition Status Phase Primary IgA Nephropathy Recruiting Phase 2 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) …

Did you know?

WebIntroduction Cystic fibrosis (CF) is a multisystem, life-threatening, autosomal recessive genetic disease resulting from mutations in the cystic fibrosis transmembrane … Web11 mei 2024 · ion-827359. Showing 1 - 1 of 1. Trials per page: STUDY. CONDITIONS. INTERVENTIONS. LOCATIONS. LAST UPDATED Chronic Bronchitis, COPD Trial in …

http://covidresearchtrials.com/07182024/output/report/covid/drug/drug1312.html WebA study medication called ION-827359 is being developed to treat lung disease symptoms in people with cystic fibrosis. The study medication is intended to help treat the thick mucus …

WebStrong evidence of tolerability and safety at the doses and regimens tested is demonstrated and supports further investigation of ENaC ASO ION-827359 in patients with cystic … WebA Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple …

http://www.nlorem.org/wp-content/uploads/2024/09/Crooke_NRDD-2024_Antisense-Overview.pdf

WebION-827359: Source: Code English cofirasersen [INN] Source: Common Name English Code System Code Type Description; INN: Source: 11517. Created by admin on Sun … lithia elementaryWeb3 mei 2024 · Safety and Tolerability Demonstrated with Inhaled αENaC Antisense Oligonucleotide (ION-827359) in Patients with Cystic Fibrosis May 2024 DOI: … lithia employmentWeb27 aug. 2024 · A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and … imprinted ice cubesWebBackground: Eluforsen is an antisense oligonucleotide designed to bind to the mRNA region around the F508-encoding deletion and restore the cystic fibrosis transmembrane … lithia employeeWeb29 mrt. 2024 · We Are Transforming the Standard of Care and Pioneering New Markets As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused … imprinted in my heart meaningWeb1 jan. 2024 · YPT-01 is an inhaled phage therapy for the treatment of P. aeruginosa infections in patients with CF. A Phase 1/2 study was initiated in early 2024 [310]. AP … lithia employee email loginWebA Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple … lithia employee handbook